François Blondel
CEO, Managing Director @ kitozyme
Brussels, Belgium
François Blondel is a funding round investor at kitozyme in Brussels focused on Biopharma and Biotechnology. François Blondel is the CEO, Managing Director of kitozyme. He previously worked at Union Wallonne des Entreprises as a Director. François Blondel attended Institute of Pure Economics at UCLouvain.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries François Blondel invests in
Stages François Blondel invests in
Countries François Blondel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Funding Round 1 (33%)
- Venture - Series Unknown 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EyeD Pharma
|
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life. | $51M / Venture - Series Unknown / Dec 24, 2021 | |
|
EyeD Pharma
|
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life. | $30.7M / May 20, 2019 | |
|
EyeD Pharma
|
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life. | $31.3M / Venture - Series Unknown / May 20, 2019 |
Co-Investors
About kitozyme
KitoZyme designs, manufactures and markets medical devices, food supplements and oenological ingredients from non-animal chitosan and chitin-glucan. KitoZyme is focused on providing solutions and outstanding services to our customers. KitoZyme is renowned for continually delivering new products and closely assisting our clients at every moment.Forever innovating, we are the long term partner that successfully produces complete solutions and helps create the future portfolios of clients all over the world.These solutions mainly come in the form of medical devices that are based on unique and patented technologies, namely chitosan and chitin-glucan manufactured from non-animal and non-GMO sources. Both the performance and safety of all of these technologies are scientifically and clinically proven.
kitozyme Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
François Blondel
CEO, Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does François Blondel invest in?
François Blondel invests primarily in Biopharma, Biotechnology and Pharmaceutical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact François Blondel?
Public channels for François Blondel include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did François Blondel last invest?
The most recent investment recorded for François Blondel closed in Dec 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
